PFE
$29.80+0.03%
as of close, Oct 27, 2026
☾ AH $29.80 +0.03%
PFE — Pfizer Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDEDDEDEEDDEDEDEEDDEEDDEEDDEEDDEEDDEEDDEDEDE
25.030.035.040.045.050.055.00500.0M$29.80—20162019202120242026
2026-10-27
Price$29.80
MA20$26.74
MA50$26.20
Vol107.2M
Key stats#
Price data
- Price
- $29.80
- YTD price return
- +19.68%
- YTD total return
- +25.86%
- Next earnings
- Nov 3, 2026 · Before open
- Market cap
- 169.9B
- Enterprise value
- 235B
- Shares outstanding
- 5.7B
- 52W low
- $23.62
- 52W high
- $30.44
- From 52W high
- -2.10%
- From 52W low
- +26.16%
- 52W range
- 91%
- Beta
- 0.33
Volume
- Rel volume
- 0.76×
- 30D volume
- 30.9M
- 30D $ vol
- 882.3M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- +$2.9M
- Insider net 1Y
- +$2.8M
Form 4 transactions by trade date, as filed; latest on file 2026-08-12.
Fundamentals
- Sales (ttm)
- 63.7B
- Sales/share
- $11.18
- EPS (ttm)
- $0.76
- FCF (ttm)
- 11B
- FCF/share
- $1.93
- Book value/share
- $14.95
- Net margin
- 6.80%
- ROE
- 5.09%
- ROA
- 2.15%
- Debt / equity
- 0.71×
- Current ratio
- 1.27
Growth (CAGR, ttm) · 10Y
- Sales
- -0.22%-12.41%+2.95%+1.99%
- Net income
- -59.84%-41.46%-19.48%-4.75%
- FCF
- -11.72%+0.99%-12.31%-2.21%
- Shares
- +0.25%+0.32%+0.33%-0.62%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -59.91%-41.43%-19.65%-3.95%
- Sales/share
- -0.46%-12.77%+2.61%+2.46%
- FCF/share
- -11.94%+0.67%-12.60%-1.60%
- Book value/share
- -4.20%-5.21%+3.66%+3.75%
- Dividend/share
- +0.59%+1.81%+2.11%+4.02%
- Price
- +20.32%-0.34%-7.06%-0.31%
- Total return
- +28.77%+6.27%-2.01%+4.32%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 39.3×
- Fwd P/E
- 10.4×
- P/S (ttm)
- 2.7×
- P/B (mrq)
- 2.0×
- P/FCF (ttm)
- 15.5×
- EV/EBITDA (fy)
- 17.5×
- EV/Sales (ttm)
- 3.7×
- FCF yield (ttm)
- 6.47%
- Dividend yield (fwd)
- 5.77%
- Dividend yield (ttm)
- 5.77%
- Dividend/share (fwd)
- $1.72
- Buyback yield (realized, 1y)
- -0.25%
- Shareholder yield (realized, 1y)
- 6.87%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 5.76%
Vs own 10Y history
- P/E
- 97th
- P/S
- 32nd
- P/B
- 31st
- P/FCF
- 59th
Bar = where today’s multiple sits in PFE’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
+0.03%
5D
-1.03%
1M
+3.94%
3M
+20.79%
YTD
+19.68%
1Y
+20.31%
5Y
-30.65%
Recent filings#
- Aug 12Insider buy · BOURLA ALBERT (Chairman & CEO · Director) bought 38,000 shares for $1.0M at $26.34
- Aug 5Insider buy · BLAYLOCK RONALD E (Director) bought 39,231 shares for $999K at $25.46
- Aug 5Insider buy · Buckley Mortimer J (Director) bought 37,632 shares for $960K at $25.52
- Aug 5Insider sale · DAMICO JENNIFER B. (SVP & Controller) sold 3,278 shares for $83K at $25.40
- Aug 4Earnings · Earnings release — EPS $0.77 vs $0.68 est. (+13.2%); revenue $15.03B (+3% y/y) 1.5%
Financial statements
Open full PFE financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
